Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China

BackgroundIn the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib (NI + CA) has shown efficacy for advanced renal cell carcinoma. This study aims to evaluate the impact of the health and economic outcomes of NI + CA in China.MethodsClinical efficacy data were derive...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hao Wang, Ye Wang, Li Li, Han Zhou, Shang Lili, Liao Li, Shen Yike, Ma Aixia
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-09-01
coleção:	Frontiers in Public Health
Assuntos:	cost-effectiveness nivolumab cabozantinib partitioned survival renal cell carcinoma
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fpubh.2022.954264/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!